trending Market Intelligence /marketintelligence/en/news-insights/trending/VjfxST9Go7A139SbnWn_SQ2 content esgSubNav
In This List

Pfizer acquires AstraZeneca's antibiotics business

Blog

Commercial Banking: June 22nd Edition

Blog

Understanding Loss Given Default A Review of Three Approaches

Blog

Commercial Banking Newsletter June Edition - 2022

Blog

Insight Weekly: US recession outlook; mortgage activity slowdown; climate disclosure push


Pfizer acquires AstraZeneca's antibiotics business

Pfizer Inc. acquired AstraZeneca PLC's late-stage antibiotics business for an upfront payment of $550 million.

AstraZeneca will receive another $175 million in January 2019 and is eligible for $250 million in commercial, manufacturing and regulatory milestones.

Pfizer will also pay up to $600 million in sales-related payments as well as recurring, double-digit royalties on sales of Zavicefta and ATM-AVI in certain markets.